IP Library Granted Patent US 11,147,876
Granted Patent B2
US 11,147,876 · App. 16/304,611 · Granted Oct 19, 2021

Anaerobic blood storage and pathogen inactivation method

Inventors: Samuel O. Sowemimo-Coker (Dix Hills, NY); Jeffrey Sutton (Medway, MA); Tatsuro Yoshida (West Newton, MA)
Assignee: Hemanext Inc.
A61K41/17A61K35/18A61L2/0047A61L2/0076A61L2/0082A61L2202/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,147,876
App. No.
16/304,611
Granted
Oct 19, 2021
Kind
B2
Abstract

A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.

Claims (18)

1. A method for blood pathogen reduction having reduced hemolysis for use in blood transfusion comprising:

removing oxygen from a red blood cell containing blood product to prepare an oxygen reduced blood product having an oxygen saturation (SO2) of less than 25%;

reducing blood pathogens from said oxygen reduced blood product comprising:

adding riboflavin to a final concentration of between 40 to 60 μM and

irradiating said riboflavin containing oxygen reduced blood product with UV light between 265-400 nm at a UV dosage of between 3.2 to 7.0 J/cm 2 to prepare pathogen reduced and oxygen reduced red blood cell containing blood product;

wherein hemolysis in said pathogen reduced and oxygen reduced red blood cell containing blood product is reduced compared to a pathogen reduced blood product that is a non-oxygen reduced blood product.

2. The method of claim 1 , further comprising storing said pathogen reduced and oxygen reduced red blood cell containing blood product under anaerobic conditions.

3. The method of claim 1 , further comprising reducing carbon dioxide from said oxygen reduced red blood cell containing blood product.

4. The method of claim 1 , wherein red blood cell hemolysis is less than 0.2% at 14 days.

5. The method of claim 1 , wherein said pathogen reduced and oxygen reduced red blood cell containing blood product is whole blood, leukoreduced whole blood, or packed red blood cells.

6. The method of claim 1 , wherein said red blood cell containing blood product further comprises reduced microparticle formation compared to an oxygenated blood.

7. The method of claim 6 , wherein the number of microparticles is reduced by at least two fold at 14 days relative to a pathogen reduced blood product treated in the presence of oxygen.

8. The method of claim 1 , wherein said red blood cell hemolysis is less than 0.4% at 21 days.

9. The method of claim 1 , wherein said red blood cell hemolysis is less than 0.5% at 28 days.

10. The method of claim 1 , wherein said red blood cell hemolysis is less than 0.8% at 35 days.

11. The method of claim 1 , wherein said red blood cell hemolysis is less than 1.2% at 42 days.

12. The method of claim 6 , wherein the number of microparticles is reduced by at least 2 fold at 21 days relative to a sample treated in the presence of oxygen.

13. The method of claim 6 , wherein the number of microparticles is reduced by at least 2 fold at 42 days relative to a sample treated in the presence of oxygen.

Assignments (3)
CHANGE OF NAME Recorded Apr 16, 2020
From: NEW HEALTH SCIENCES, INC.
To: HEMANEXT INC.
Reel/Frame 052630/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2019
From: SUTTON, JEFFREY; YOSHIDA, TATSURO
To: NEW HEALTH SCIENCES, INC.
Reel/Frame 049241/0012 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2019
From: SOWEMIMO-COKER, SAMUEL O.; SUTTON, JEFFREY; YOSHIDA, TATSURO
To: NEW HEALTH SCIENCES, INC.
Reel/Frame 049241/0045 →
Continuity (3)
Provisional Application 62342756 · May 27, 2016
Provisional Application 62445081 · Jan 11, 2017
Related Publication 20190167792A1 · Jun 6, 2019
Cited By (1)
US 12,551,586